Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing-and fast

Carlos Aguado; Unai Jiménez Maestre; Xabier Mielgo-Rubio

doi:10.5306/wjco.v13.i9.758

Neoadjuvant immunotherapy in non-small-cell lung cancer: Times are changing-and fast

World J Clin Oncol. 2022 Sep 24;13(9):758-761. doi: 10.5306/wjco.v13.i9.758.

Authors

Carlos Aguado¹, Unai Jiménez Maestre², Xabier Mielgo-Rubio³

Affiliations

¹ Department of Medical Oncology, Hospital Universitario Clínico San Carlos, Madrid 28040, Spain. carlos.aguado84@gmail.com.
² Department of Thoracic Surgery, Hospital Universitario Cruces, Barakaldo 48903, Bizkaia, Spain.
³ Department of Medical Oncology, Hospital Universitario Fundación Alcorcón, Alcorcón 28922, Madrid, Spain.

Abstract

Recent data from a phase 3 trial have shown that the addition of immunotherapy to neoadjuvant chemotherapy improves event-free survival in patients with non-small-cell lung cancer (NSCLC). This is the first positive phase 3 trial in this setting, although several phase 3 trials are currently investigating the efficacy of neoadjuvant and adjuvant immunotherapy in resectable NSCLC.

Keywords: Checkmate-816; Chemo-immunotherapy; Immunotherapy; NSCLC; Neoadjuvant; Perioperative; nivolumab.